Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials
Study limitation reported by the research below: “The active comparator, teriflunomide, is a moderate-efficacy agent; superiority over it does not establish remibrutinib's place relative to high-efficacy MS therapies.”